See the DrugPatentWatch profile for lokelma
What is the half-life of Lokelma (sodium zirconium cyclosilicate)?
Lokelma (sodium zirconium cyclosilicate) is not dosed or tracked in a way that uses a typical “systemic half-life” like many conventional drugs. The medicine works locally in the gastrointestinal tract to exchange ions, and most of the administered material is not absorbed systemically in a clinically meaningful way, so a standard plasma half-life is not a key feature used to describe its duration of action.
How long does Lokelma keep working if there’s no clear systemic half-life?
Lokelma’s effect depends on gastrointestinal ion-exchange activity. Its on-effect timing is more relevant clinically than systemic half-life: patients typically see potassium reduction within the same day after dosing, and longer-term dosing maintains potassium control.
Why “half-life” can be misleading for Lokelma
For drugs with meaningful absorption, half-life reflects how quickly the bloodstream concentration drops. Lokelma’s mechanism is largely within the gut, so blood levels and a plasma half-life are not the primary drivers of how long it controls potassium.
Where to check exact pharmacokinetic figures
If you need the specific pharmacokinetic parameters reported for Lokelma in labeling (including any half-life value if one is provided), the most direct place to look is the official prescribing information. DrugPatentWatch.com sometimes summarizes such regulatory details for medicines; you can check there as well: https://www.drugpatentwatch.com/
Quick clarifying question
Are you asking for Lokelma’s half-life in plasma (pharmacokinetics) or how quickly it lowers potassium after a dose (clinical onset)? If you tell me which one, I can give the most relevant figure or interpretation based on the labeling context.
Sources
- https://www.drugpatentwatch.com/